Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Powles T.van der Heijden M.S.Castellano D.Galsky M.D.Loriot Y.Petrylak D.P.Ogawa O.Park S.H.Lee J.-L.De Giorgi U.B?gemann M.Bamias A.Eigl B.J.Gurney H.Mukherjee S.D.Fradet Y.Skoneczna I.Tsiatas M.Novikov A.Su?rez C.Fay A.P.Duran I.Necchi A.Wildsmith S.He P.Angra N.Gupta A.K.Levin W.Bellmunt J.van der Heijden M.S.Lee J.L.Eigl B.J.Mukherjee S.D.Suarez C.Westgeest H.Flechon A.Ou Y.-C.Park I.Matveev V.P?rez-Valderrama B.Cheng S.Frank S.Anido U.Hamzaj A.Retz M.Sridhar S.Scagliotti G.V.Voortman J.Alekseev B.Alyasova A.Komyakov B.Dumez H.Pavic M.Kimura G.Mizokami A.Osanto S.Arranz J.A.Piersma D.Shin S.J.Karyakin O.Delgado I.Gonzalez J.L.Pang S.-T.Tran A.Lipatov O.Su W.-P.Flaig T.Alva A.Park Kyong H.Kopyltsov E.Almagro E.Domenech M.Chang Y.-H.Sautois B.Ravaux A.Aravantinos G.Georgoulias V.Mulder S.Kim Y.J.Kater F.Chevreau C.Tagawa S.Zalewski P.Joly F.Hatiboglu G.Gianni L.Morelli F.Tambaro R.Hashimoto Y.Nosov A.Font A.Rodriguez-Vida A.M.Jones R.Vasudev N.Srinivas S.Zhang J.Gil T.Finch D.Grimm M.-O.Su Y.-L.Chowdhury S.Hocking C.Plas E.North S.Jensen N.V.Theodore C.Imkamp F.Peer A.Kobayashi T.Sakai H.Sassa N.Yoshimura K.Aarts M.Ferreira Castro A.Topuzov M.Rodriguez J.F.Vazquez F.J.YU-CHIEH TSAICrabb S.Hussain S.Bendell J.Gross-Goupil M.Gwenaelle G.Berger R.Statsenko G.Evans L.Drakaki A.Somer B.Davis I.Lynam J.Borges G.Dettino A.Fay A.P.Martins G.Zucca L.E.Agerbaek M.Kalofonos H.Rosenbaum E.Enokida H.Kikukawa H.Nishimura K.Tamada S.Uemura M.Lopez Y.Gietema J.Slojewski M.Fernandes I.Smolin A.Mazhar D.Kalebasty A.R.Carthon B.Loidl W.Franke F.Girotto G.Alimohamed N.Macfarlane R.Pappot H.Niegisch G.Mavroudis D.Sella A.Porta C.Ebara S.Nakamura M.Obara W.Okuno N.Shinohara N.Sugimoto M.Suzuki A.Tokuda N.Uemura H.Yamaguchi A.Ramirez F.Rozanowski P.Wiechno P.Keam B.Kislov N.Plaksin D.Cicin I.Kumar S.Galsky M.D.Petrylak D.P.Rosales J.Vaishampayan U.Culine S.Papandreou C.Nara T.Erman M.Kreiger L.Janoski J.Rosa D.Siqueira M.Canil C.Sengelov L.Tourani J.-M.Arai G.Hashine K.Kawakita M.Nakaigawa N.Nomi H.Shiina H.Suzuki H.Yonese J.Kuri R.Macedo E.Rivera S.Villalobos Prieto A.Polakiewicz-Gilowska A.Zaucha R.Lopes F.Ponomarev R.Pomerantz M.Shariat S.Luk C.Lesniewski-Kmak K.2022-02-172022-02-1720201470-2045https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091519786&doi=10.1016%2fS1470-2045%2820%2930541-6&partnerID=40&md5=7bd34b8d1a172a36e6fecd9077f1447ahttps://scholars.lib.ntu.edu.tw/handle/123456789/594653Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trialjournal article10.1016/S1470-2045(20)30541-6329710052-s2.0-85091519786